Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

10x Genomics Offerings Not Yet Big Enough to Offset Core Business Deceleration - GS

Published 08/19/2022, 03:28 AM
Updated 08/19/2022, 03:28 AM
© Reuters.

© Reuters.

By Sam Boughedda

A Goldman Sachs analyst downgraded shares of 10x Genomics (NASDAQ:TXG) to Sell from Neutral in a note Thursday, lowering the price target to $35 from $55.

The analyst said they expect a "materially slower cadence" to the company's 2023/24 sales growth rate vs consensus (and historically) as it transitions to a multi-market, multi-product company.

The analyst's and Goldman's price target represents an 18% downside for 10x Genomics shares. They have fallen 7.7% during today's session and are down more than 73% in 2022.

"We believe the durable growth rate for their single cell analysis business is below what Factset consensus has modeled over the next few years as their penetration into the academic market has hit a ceiling amongst the high utilization, core lab customers," explained the analyst. "Case in point, their 'halo' customer base who do not own Chromium instruments has grown to over 50% of their customer base but less than 50% of their revenues. We believe this dynamic is an indication that, for the time being, TXG has reached a certain penetration rate amongst the large, core lab customers."

"While we believe over the longer term, TXG can reaccelerate growth in single cell by expanding into the Biopharma and Diagnostic end markets, the spatial and in situ offerings are not yet of the size to help offset the deceleration in their core business," he added.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.